Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer
To discover if the adding of a coxib increases the efficacy of the Aromasine.
Metastatic Breast Cancer
DRUG: placebo|DRUG: Celecoxib|DRUG: Exemestane
Progression free survival, 5 years
Objective response rate, 6 months|Quality Of Life + pain, 6 months|Overall survival, 5 years|Tolerance, 6 months
To discover if the adding of a coxib increases the efficacy of the Aromasine.